Antidiabetic potential of developed solid lipid nanoparticles loaded with quercetin: In vitro and in silico studies

Abstract

Development of the novel formulation is critically needed for alleviating several acute and chronic ailments.Diabetes is acknowledged as one of the prevalent metabolic disorder affecting the global health and economy, vigorously.Based on the above facts, the study is aimed to develop SLNs (solid lipid nanoparticle) loaded with quercetin as the potential novel formulation for the management of diabetes.Preformulation and postformulation studies were conducted to determine the purity and compatibility of quercetin with the formulation bases used for its development.a-amylase and a-glucosidase inhibitory activity and DPPH (2, 2-diphenyl-1-picrylhydrazy) free radicals scavenging activity were performed of the developed formulation with the comparison of the control group quercetin to determine antidiabetic and antioxidant potential.Network pharmacology analysis was performed to determine the multimechanistic and therapeutic potential of quercetin for treatment of diabetes and its associated complications.The results showed that quercetin was found substantially compatible with the formulation bases used for its development.The particle size of the developed SLNs was found with no drug interaction with the formulation base which was evaluated from the FTIR (Fourier transform infrared spectroscopy) analysis.In antidiabetic analysis of the formulation, no significant (p<0.05)variance was found in the aamylase and a-glucosidase activity while DPPH activity of the developed SLNs was found 81% at the higher concentration.In network pharmacology analysis, it was found that quercetin regulates several genomes such as IRS-1, TLRs, ILs, CASPs, MAPKs, AKT1, AOX, etc., involved in the diabetes and its associated complication.Hence, it can be concluded that the developed SLNs not only regulates diabetes even effect for the diabetes associated complication.